Key facts
- syntelios’s last known valuation is $84.1M (Mar 2025).
- It has raised $55.2M; the latest was Early Stage VC ($55.2M) in Mar 2025.
- Notable investors include Samsara BioCapital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for syntelios
- ·The full record, as it builds
Funding rounds
No funding rounds for syntelios are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About syntelios
Provider of research and development services based in Zürich, Switzerland. The company offers research and development services in physical and natural sciences, preclinical and clinical research, discovery, and development of new drugs, drug combinations, diagnostics, and biomarkers for antibody-based therapies and small molecules for the treatment of cancer, immune system diseases.
- Sector
- Healthcare
- HQ
- Zürich, Switzerland
- Founded
- 2024
- Ownership
- Privately Held (backing)
syntelios doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in syntelios shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on syntelios in its N-PORT filings yet. We sweep new filings monthly.